What is the risk of breast cancer associated with hormone therapy (HRT) for menopausal symptoms?

Breast Cancer Risk with HRT for Menopausal Symptoms

The absolute risk of breast cancer from HRT is modest and depends critically on formulation: estrogen-alone therapy does NOT increase breast cancer risk and may actually reduce it, while combined estrogen-progestogen therapy causes a small, duration-dependent increase of approximately 8 additional cases per 10,000 women per year. 1, 2, 3

Risk Stratification by HRT Type

Estrogen-Alone Therapy (Post-Hysterectomy)

• Reduces breast cancer incidence (HR 0.77,95% CI 0.62-0.95) 2
• Decreases breast cancer mortality (HR 0.37) 2
• Absolute risk reduction: 8 fewer cases per 10,000 woman-years 3
• This protective effect persists through nearly 11 years of follow-up 2

Combined Estrogen-Progestogen Therapy

• Increases breast cancer risk (HR 1.25,95% CI 1.07-1.46) 2
• Absolute risk increase: 8 additional cases per 10,000 woman-years 4, 3
• Risk is duration-dependent and becomes statistically significant after 5+ years of use 1

Critical nuance: The WHI study's widely-cited HR of 1.26 for combined therapy did not reach statistical significance (95% CI 1.00-1.59, which includes 1.0), and when adjusted for prior MHT exposure, showed no increased risk in women without previous MHT use 1

Duration-Dependent Risk Profile

The risk increases proportionally with duration of use:

• Years 1-4: Minimal increase (RR 1.60 for E+P; RR 1.17 for estrogen-alone) 5
• Years 5-14: Greater increase (RR 2.08 for E+P; RR 1.33 for estrogen-alone) 5
• 15+ years: RR reaches 1.6 for combined therapy 1

Important caveat: Even with 10+ years of combined E+P therapy, the absolute excess risk remains confined to approximately 0.75% 1

Progestogen Selection Matters

The type of progestogen significantly influences breast cancer risk:

• Micronized progesterone: More favorable breast cancer risk profile than synthetic progestins 6, 7, 8
• Daily progestogen: Higher risk (RR 2.30) compared to intermittent use (RR 1.93) during years 5-14 5
• Specific formulations with increased risk: EH/drospirenone (HR 1.51), EH/NETA (HR 1.66), EH/dydrogesterone (HR 1.37), and EV/cyproterone acetate (HR 1.74) 9
• Medroxyprogesterone acetate: Associated with higher risk in observational studies 1

Risk Modification by Patient Factors

Body Weight

• Lean women: Higher HRT-related breast cancer risk 10
• Obese women: Little to no excess risk from estrogen-alone therapy 5
• The protective adipose tissue effect attenuates HRT-associated risk 5

Breast Density

• Women with dense breasts have higher HRT-related breast cancer risk 10
• Combined HRT increases mammographic density, potentially compromising cancer detection 11

Age at Initiation

• Similar relative risks for women starting MHT at ages 40-59 years 5
• Risk attenuated when starting after age 60 5

Family History

• Family history of breast cancer does NOT further increase risk from MHT use (RR 1.13,95% CI 0.82-1.57) 1

Risk After Discontinuation

Risk persists but diminishes after stopping MHT:

• Excess risk disappears 1-5 years after discontinuation 1
• Magnitude of residual risk depends on duration of prior use 5
• Little excess risk following less than 1 year of use 5

Clinical Decision Algorithm

For Women WITH a Uterus (Requiring Combined Therapy):

1. Counsel on absolute risk: 8 additional breast cancers per 10,000 women per year 4, 3
2. Prefer micronized progesterone or dydrogesterone over synthetic progestins 7, 8
3. Use lowest effective dose for shortest duration needed for symptom control 4
4. Reassess annually after 5 years of use when risk becomes more substantial 1

For Women WITHOUT a Uterus (Estrogen-Alone):

1. Reassure about breast cancer risk: Estrogen-alone does NOT increase risk and may reduce it 2, 3
2. This is the preferred regimen from a breast cancer perspective 2
3. Duration can extend longer than combined therapy without breast cancer concern 2

Special Populations:

BRCA1/BRCA2 carriers post-oophorectomy: HRT up to age 51 does NOT increase breast cancer risk or negate protective effect of surgery 12

Breast cancer survivors: HRT is contraindicated due to increased recurrence risk (3-fold increase in RCT) 11, 13. Low-dose vaginal estrogen for genitourinary symptoms may be considered with oncology consultation 12, 11

Common Pitfalls to Avoid

1. Overestimating relative risk: The widely-cited 26% increased risk (HR 1.26) from WHI was not statistically significant and applies only to one specific formulation (CEE-medroxyprogesterone) 1

2. Ignoring observational bias: Studies showing increased risk in year 1 of therapy likely reflect detection of pre-existing disease, not causation 1

3. Failing to distinguish formulations: Estrogen-alone and combined therapy have opposite effects on breast cancer risk 2, 3

4. Not considering patient-specific factors: Obesity, breast density, and age modify risk substantially 10, 5

5. Applying population data to individuals: 82% of studies from 1975-2000 showed no significant breast cancer risk increase 1

Quantifying Absolute Risk

For perspective on the 5-year absolute risk 4:

• 8 more invasive breast cancers per 10,000 women
• 7 more CHD events per 10,000 women
• 8 more strokes per 10,000 women
• 8 more pulmonary emboli per 10,000 women
• BUT 6 fewer colorectal cancers per 10,000 women
• AND 5 fewer hip fractures per 10,000 women

The net harm-benefit ratio depends on individual baseline risks for these conditions and personal values regarding quality of life versus small absolute risk increases.